Integra LifeSciences Holdings
$ 12.41
-1.90%
16 Jan - close price
- Market Cap 966,873,000 USD
- Current Price $ 12.41
- High / Low $ 12.70 / 12.34
- Stock P/E N/A
- Book Value 13.33
- EPS -6.47
- Next Earning Report 2026-02-24
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.03 %
- ROE -0.39 %
- 52 Week High 27.13
- 52 Week Low 10.87
About
Integra LifeSciences Holdings Corporation (IART) is a premier global medical technology firm based in Princeton, New Jersey, dedicated to creating cutting-edge surgical implants and medical devices tailored for diverse applications such as neurosurgery, limb reconstruction, orthopedics, and general surgery. Renowned for its commitment to improving patient outcomes, the company harnesses proprietary technologies and robust research initiatives to provide innovative solutions that effectively address unmet medical needs. With a strategic focus on capitalizing on growth opportunities within the dynamic healthcare sector, Integra is positioned to enhance shareholder value and drive long-term success in an increasingly competitive market.
Analyst Target Price
$15.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-30 | 2025-07-31 | 2025-05-05 | 2025-02-26 | 2024-11-04 | 2024-07-29 | 2024-05-06 | 2024-02-28 | 2023-10-25 | 2023-07-26 | 2023-04-26 | 2023-02-22 |
| Reported EPS | 0.54 | 0.45 | -0.3308 | 0.97 | 0.41 | 0.63 | 0.55 | 0.89 | 0.76 | 0.71 | 0.74 | 0.94 |
| Estimated EPS | 0.43 | 0.44 | 0.4311 | 0.8554 | 0.39 | 0.62 | 0.55 | 0.9 | 0.78 | 0.57 | 0.74 | 0.9 |
| Surprise | 0.11 | 0.01 | -0.7619 | 0.1146 | 0.02 | 0.01 | 0 | -0.01 | -0.02 | 0.14 | 0 | 0.04 |
| Surprise Percentage | 25.5814% | 2.2727% | -176.7339% | 13.3972% | 5.1282% | 1.6129% | 0% | -1.1111% | -2.5641% | 24.5614% | 0% | 4.4444% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-24 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.8 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | |
|---|---|
| Payment Date | None |
| Amount | $6.37 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IART
2026-01-07 04:10:49
Integra LifeSciences Holdings C (IART) shows a potential upside of 23.41% despite mixed financial performance, including positive revenue growth but negative EPS and ROE. The company, which operates in the medical devices industry, has strong free cash flow and reinvests earnings, facing varied analyst sentiment with an average target price of $15.50. Technical indicators suggest an overbought condition, emphasizing the need for investors to monitor sector trends and company developments closely.
2026-01-06 01:09:39
Integra LifeSciences Holdings Corporation announced that its CEO, Mojdeh Poul, and CFO, Lea Knight, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 2:15 p.m. ET. A live webcast of the presentation will be available on the company's investor relations website, providing broad access to their discussion on innovative treatment pathways in surgical, neurologic, and regenerative care. The company's participation highlights its standing in the medical technology sector and its commitment to engaging with investors.
2026-01-05 21:09:39
Integra LifeSciences Holdings Corporation announced that CEO Mojdeh Poul and CFO Lea Knight will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 2:15 p.m. ET. A live webcast of their presentation will be available on the company's investor relations website. Integra LifeSciences is a global medical technology company focused on surgical, neurologic, and regenerative care.
2026-01-05 07:28:12
Integra LifeSciences Holdings Corporation announced that its CEO, Mojdeh Poul, and CFO, Lea Knight, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The presentation will be available via live webcast on the company's investor relations website. Integra LifeSciences is a medical technology company focused on restoring patients' lives through innovative treatment pathways.
2025-12-17 13:09:09
Seven brokerages have issued a "Reduce" consensus rating for Integra LifeSciences Holdings Corporation (NASDAQ:IART), with an average 1-year price target of $15.00. This rating follows mixed quarterly results, where the company beat EPS expectations but missed revenue estimates and provided lower-than-analyst-expected Q4 and FY2025 guidance. Insider activity shows a director increasing their stake, while institutional investors hold a significant portion of the stock.
2025-12-17 00:10:16
Integra LifeSciences (IART) has seen an 11% rebound recently, contrasting with a 40% year-down performance. Despite modest growth and losses, analysts suggest it is 15.5% undervalued with a fair value of $15.88, driven by strategic investments and cost optimization. The narrative emphasizes a potential future recovery and profit profile that could lead to double-digit upside.
